==== Front Cureus Cureus 2168-8184 Cureus 2168-8184 Cureus Palo Alto (CA) 10.7759/cureus.39825 Radiology Infectious Disease Pulmonology Lung Cavitation as a Long-Term Imaging Pattern of COVID-19 Muacevic Alexander Adler John R Çınar Caner 1 Kocakaya Derya 2 Olgun Yıldızeli Sehnaz 1 Karakurt Sait 2 1 Pulmonology Department, Marmara University, Istanbul, TUR 2 Pulmonology Department, Marmara University School of Medicine, Istanbul, TUR Caner Çınar dr.canercinar@gmail.com 1 6 2023 6 2023 15 6 e398251 6 2023 Copyright © 2023, Çınar et al. 2023 Çınar et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This article is available from https://www.cureus.com/articles/151420-lung-cavitation-as-a-long-term-imaging-pattern-of-covid-19 Background A wide variety of radiological imaging findings, especially CT findings, have been reported in patients with COVID-19 pneumonia during the pandemic surge. Generally, on control chest imaging, individuals who have been cured of the disease usually show complete remission; however, in severe cases, residual pulmonary fibrosis, other abnormalities, and, rarely, lung cavitation can be observed. In this retrospective descriptive study, we aimed to describe the clinical, radiological, and laboratory characteristics of patients who developed lung cavitation in the course of SARS-CoV-2 disease recovery. Methodology Over a period of five months from March 1, 2021, to August 1, 2021, 15 consecutive patients who developed cavitary lesions on chest CT during the course of recovery from COVID-19 were recruited as the study population. All patients had a history of a SARS-CoV-2 infection diagnosed with a positive real-time polymerase chain reaction test. Patients who already had cavitary lesions in chest CT during the start of COVID-19 symptoms were excluded. Results In this study, 14 patients were male (93.3%). The only female patient was the only severely obese patient in the study population, with a body mass index was 40.4 kg/m2. The median (range) age of the patient population was 61 (42-79) years. Eight patients (53.3%) required intensive care unit admission during the hospitalization period. Three patients who required intensive care unit were intubated and needed invasive mechanical ventilation. Two patients died during hospitalization. Conclusions Lung cavitation remains a rare occurrence in the course of COVID-19. Bronchoscopic evaluation and scanning for pulmonary embolism should be done in appropriate patients to determine secondary reasons for cavitation. Although this descriptive study showed that cavitary lesions can develop in patients with severe disease, more comprehensive studies with a control group are needed to reach a definitive conclusion. long covid-19 post-covid-19 computerized tomography lung cavitation covid-19 ==== Body pmcIntroduction During the last months of 2019, the SARS-CoV-2 outbreak began in Wuhan, China. On March 2020, the WHO declared COVID-19 a global pandemic [1]. The highly contagious pneumonia caused by the COVID-19 pandemic spread quickly around the world and resulted in millions of deaths. Mild COVID-19 is characterized by fever, malaise, cough, upper respiratory symptoms, and/or less common features of COVID-19, in the absence of dyspnea. The majority of patients do not need to be hospitalized. Patients generally require hospitalization if they experience dyspnea, which raises concerns that they have a condition of at least moderate severity. Patients may have infiltrates on chest imaging and still be thought to have a moderate illness, but the presence of any of the following signs or symptoms suggests severe disease: hypoxemia (oxygen saturation 94% on room air), the requirement for oxygenation, or ventilatory support [2]. In cases of moderate or early illness, chest radiographs may be normal. In a retrospective analysis of 64 COVID-19 patients in Hong Kong, 20% never had any abnormal chest radiograph findings at any stage in the disease [3]. Consolidation and ground-glass opacities with bilateral, peripheral, and lower lung zone distributions were frequent abnormal radiographic findings. Lung involvement developed throughout the course of the illness, reaching a peak in severity 10 to 12 days following the onset of symptoms. A wide variety of radiological imaging findings, especially chest CT findings, have been reported in patients with COVID-19 pneumonia. Although some chest CT abnormalities may be indicative of COVID-19 and chest CT may be more sensitive than a chest radiograph, no CT finding can definitively confirm or deny the presence of COVID-19. Chest CT should only be used for hospitalized patients when needed for treatments, according to the Society of Thoracic Radiology, the American College of Radiology, and the Radiological Society of North America which warn against using CT for COVID-19 screening or diagnosis [4]. Most frequently, ground-glass opacification with or without consolidative abnormalities is seen on chest CT in COVID-19 patients, which is consistent with viral pneumonia. On control chest imaging, individuals who have been cured of the disease usually show complete remission; however, in severe cases, residual pulmonary fibrosis and other abnormalities can be observed [5]. Long-term imaging or sequelae pattern of COVID-19 is not well defined yet. In this study, our aim was to describe the clinical, radiological, and laboratory characteristics of 15 patients admitted to Marmara University Hospital between March 1, 2021, and August 1, 2021, who developed cavitary lesions in the course of SARS-CoV-2 disease recovery. Materials and methods Patients The study was conducted at Marmara University, School of Medicine Pulmonary and Critical Care Medicine Clinic. Ethical approval was obtained from the Marmara University, School of Medicine Clinical Research Ethics Committee (approval number: 5.11.2021;1224). In this retrospective and descriptive study conducted over a period of five months from March 1, 2021, to August 1, 2021, 15 consecutive patients who developed cavitary lesions on chest CT during the course of recovery from COVID-19 were recruited as the study population. Patients who already had cavitary lesions on chest CT during the start of COVID-19 symptoms were excluded. Demographics and comorbidities Gender, age, concomitant conditions, body mass index (BMI), smoking status, and length of hospital stay were documented for all patients. Standard treatment Treatment planning for COVID-19 was implemented following the guidelines prepared by the Republic of Turkey, Ministry of Health [6]. Treatment modifications were made according to the patients’ daily physical examinations and laboratory findings by pulmonary medicine and critical care physicians during the hospital stay. The recommended treatment scheme according to the guidelines of the Ministry of Health is favipiravir 600 mg bid after 1,600 mg bid loading dose in patients for five days, which in severe patients can be extended up to 10 days. Low-molecular-weight heparin was given to all hospitalized patients as an anticoagulant. Patients with high oxygen demand, severe respiratory distress, and who had documented embolism were treated with enoxaparin 0.02 mg/kg/day bid per day, and clinically stable patients were treated with enoxaparin 0.01 mg/kg/day once daily. Patients who had mild hypoxemia were treated with 6 mg dexamethasone or an equivalent corticosteroid dose. For patients with higher oxygen demand, needing mechanical ventilation, and those with evolving cytokine release storm (CRS), higher doses of corticosteroids were added to the treatment regimen, and the dose was tapered according to clinical response during the hospital stay. Empiric antibacterial or antifungal treatment was administered only if there was clinical suspicion of secondary bacterial or fungal pneumonia. For patients with evolving CRS during disease surge, anti-tumor necrosis factor (TNF) tocilizumab was recommended. Initially, one dose was given, and a second dose was optional based on the clinical evolution of the patient. Laboratory parameters In all cases; lymphocyte count (×10³/μL), platelet count (×10³/µL), mean platelet volumes, neutrophil/lymphocyte count, lymphocyte/C-reactive protein (CRP) and platelet/CRP ratios, D-dimer (mg/L), CRP (mg/L), procalcitonin (μg/L), ferritin (μg/L), and lactate dehydrogenase (LDH) (U/L) findings at admission were recorded. Disease severity Clinical staging for all patients during hospitalization was calculated based on the values of the worst clinical findings during hospitalization according to the WHO progression scale [7]. Radiologic severity was assessed using CT visual quantitative evaluation from 0-20 [8]. Each lung lobe was assessed for the percentage of lobar involvement and classified as none (0%), minimal (1-25%), mild (26-50%), moderate (51-75%), or severe (76-100%), with corresponding scores of 0, 1, 2, 3, or 4. The total severity score was reached by summing the five lobe scores. All radiological scorings were done by a single expert. Patients clinically suspected of having pulmonary embolism or venous thromboembolism were evaluated with deep venous ultrasonography or pulmonary CT angiography, and those suspected to have secondary infections were evaluated for microbiological pathogens with the aid of sputum culture, blood culture, or bronchoscopic evaluation. Statistical analysis Data obtained in the study were analyzed using SPSS Statistics for Windows version 23.0 software (IBM Corp., Armonk, NY, USA). Continuous variables were stated as mean ± standard deviation (SD) and categorical data as numbers (n) and percentages (%). Results A total of 1,382 patients having COVID-19 were admitted to Marmara University Hospital Pulmonary Medicine and Critical Care clinic during the study period. Of the 1,382 patients, 15 had developed cavitary lesions during the disease course. CT images of six patients are demonstrated in Figure 1. Figure 1 CT images of six patients. Cavitary lesions are located differently in patient groups. In a and d, cavitations are located at apices. In b, c, d, and f, cavitary lesions are located at the lower lobes. Demographic features, treatments, length of hospital stay, and laboratory findings of the study population on admission are summarized in Table 1 and Table 2. Table 1 Summary of demographic features, length of hospital stay, and treatments. F: female; M: male; HT: hypertension; GERD: gastroesophageal reflux disease; TNF: tumor necrosis factor; ARB: acid-resistant bacteria; COPD: chronic obstructive pulmonary disease; CAD: coronary artery disease; CVE: cerebrovascular event *: Steroid doses converted to dexamethasone and total dose taken divided by hospitalization time when mean dexamethasone dose was calculated.   Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Patient 11 Patient 12 Patient 13 Patient 14 Patient 15 Age (years) 64 68 42 62 52 61 56 70 47 61 45 42 59 79 65 Sex F M M M M M M M M M M M M M M Comorbidities Obesity, asthma - HT - Chronic hepatitis B GERD - CAD, COPD, ischemic CVE HT, Behçet’s disease Peptic ulcers - Wegener - COPD - BMI (kg/m2) 40.4 24.5 26.5 25 23.1 26.8 25.7 29.4 26.3 28.1 27.4 31.3 26.8 28.5 27.8 Smoking history - 30 pack-years - - - 30 pack-years - 40 pack-years 20 pack-years 12 pack-years 15 packs-years 10 pack-years 15 pack-years 30 pack-years 40 pack-years Length of hospital stay (days) 45 20 55 93 48 35 22 26 34 48 70 60 30 10 15 Mean dexamethasone dose(mg/day)* 16.3 mg/day 4.1 mg/day 9.78 mg/day 5.7 mg/day 7.37 mg/day 6 mg/day 19 mg/day 6 mg/day 6.4 mg/day 15.6 mg/day 10.2 mg/day 12.4 mg/day 11.3 mg/day 11.4 mg/day 8.4 mg/day Highest dexamethasone dose taken in one day (mg) 40 mg 8 mg 20 mg 20 mg 20 mg 20 mg 3 × 250 mg methylprednisolone (mini-pulse) 10 mg 40 mg 3 × 250 mg methylprednisolone (mini-pulse) 3 × 250 mg methylprednisolone (mini-pulse) 3 × 250 mg methyl prednisolone (mini-pulse) 20 mg 20 mg 40 mg Favipiravir use 5 days 5 days 5 days 5 days 5 days 5 days 10 days 5 days 5 days 5 days 5 days 5 days 5 days 5 days 5 days Anti TNF (tocilizumab use) - - 2 doses 400 mg 1 dose 400 mg - - 1 dose 400 mg - - - 1 dose 400 mg - - - - Table 2 Laboratory findings of the patients on admission. WBC: white blood cell; MPV: mean platelet volume; LDH: lactate dehydrogenase; CRP: C-reactive protein   Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Patient 11 Patient 12 Patient 13 Patient 14 Patient15 Lymphocytes (1.5–3.1 × 10³/µL) 0.7 0.7 1.5 0.6 0.6 4.7 0.4 0.7 1.1 0.3 1.4 0.8 0.5 0.3 1.4 Neutrophil/Lymphocyte ratio 18.28 8.57 2.8 26.5 14.5 1.08 36.25 4.57 6.71 62.6 6.71 6.62 18.4 9.6 12.6 Lymphocyte/CRP ratio 60.8 8.35 17.54 2.68 8.91 758 10.6 15.6 95.4 6.52 9.45 8.55 3.2 4.68 18.18 Platelet/Lymphocyte ratio 0.016 0.47 0.172 0.63 0.173 0.05 0.775 0.22 0.15 1.01 0.06 0.27 0.31 0.91 0.16 MPV 10.1 11.1 11.2 12.1 9.3 10 10.3 10.9 10.7 12.3 12.7 11.6 11.7 9.7 11.2 Platelets (150–440 × 10³ /µL) 388 333 259 380 104 267 310 154 318 305 96 219 157 273 225 D-dimer (0–0.5 mg/L) 0.27 5.19 0.33 16.12 2.68 0.7 8.45 3.24 8.56 0.43 2.23 0.69 4.88 2.09 1.28 LDH (0–250 IU/L) 364 865 538 559 437 304 302 404 401 313 847 519 900 420 325 Ferritin (30–400 µg/L) 50.8 1647 702 946 227.8 463 773.2 386 874 100.8 1354 1204 2173 642 850 CRP (0–5 mgd/L) 11.5 83.8 85.5 223.5 67.3 6.2 37.7 44.8 22 46 148 93.5 156 64 77 Procalcitonin (0–0.5 µg/L) 0.03 0.11 0.2 0.63 1.38 0.06 0.11 0.06 0.09 0.12 0.13 0.86 2.37 0.05 0.2 In total, 14 (93.3%) patients were male. The only female patient was severely obese, with a BMI of 40.4 kg/m2. The median (range) age of the patients was 61 (42-79) years. Ten of the 15 patients had a smoking history. Two patients had been diagnosed with chronic obstructive pulmonary disease and were using inhalers. The mean length of hospital stay was 40.7 days, ranging between 10 and 93 days. Eight (53.3%) patients required intensive care unit admission during the hospitalization period. Three of the patients who required intensive care unit admission were intubated and needed invasive mechanical ventilation. Two patients died during hospitalization. Thirteen patients were discharged after treatment. All patients were treated with the antiviral drug favipiravir for at least five days and corticosteroids, with the dose adjusted and tapered according to clinical response. Dexamethasone dose ranged between 4.1 mg/day and 19 mg/day during hospitalization. The highest total dose taken by patients in one day is also shown in Table 1. Four (26.6%) had CRS, and tocilizumab was added to their regimen. In total, 13 (86%) patients had lymphopenia, 13 (86%) had elevated D-dimer titers, 11 (73.6%) had elevated ferritin levels, and all had increased LDH on admission. The neutrophil/lymphocyte ratio was above 3 in 13 (86%) patients. Lymphocyte/CRP and platelet/CRP ratios and other laboratory values on admission are also shown in Table 2. Visual quantitative evaluation scores of the study population were between 6 and 20. The mean cavitary lesion detection time after SARS-CoV-2 PCR positivity was 53.2 days (range = 23-116 days). Six (40%) patients had documented pulmonary embolism during the follow-up period. Galactomannan was positive in two patients. Two patients had Mycobacterium tuberculosis complex positivity, and five patients had grown bacterial pathogens in microbiological cultures. The longest diameter of cavitary lesions ranged between 9 and 52 mm. Cavitary lesions were located bilaterally in three patients. Other characteristics of cavitary lesions are summarized in Table 3. Table 3 Location of the cavitary lesions, microbiological culture results, documented VTE presence, and WHO clinical progression scale of patients. DVT: deep vein thrombosis; VTE: venous thromboembolism; MTB: Mycobacterium tuberculosis; BAL: bronchoalveolar lavage; DTA: deep tracheal aspirate; MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; sPE*: segmental pulmonary embolism; **: BAL cultures; ^^: sputum culture; RUL: right upper lobe; LUL: left upper lobe; RML: right middle lobe; RLL: right lower lobe; LLL: left lower lobe   WHO clinical progression scale Radiological score Documented VTE Culture results Cavitary lesion detection time after PCR positivity (days) Location of cavitary lesions Number of cavities Wall thickness of cavitary lesions Longest diameter of cavitary lesions Patient 1 5 6 Bilateral sPE* MTB complex** 42 RLL 2 4 mm 13 mm Patient 2 5 9 Left femoral vein DVT+bilateral sPE* -** 23 LLL 2 5.6 mm 12 mm Patient 3 6 12 - Galactomannan+** 52 RUL 2 8 mm 39 mm Patient 4 9 20 - K. pneumonia** 56 RUL+LUL 2 3.1 mm 18 mm Patient 5 6 15 Bilateral sPE* MTB complex** 58 LLL 2 3.9 mm 16 mm Patient 6 6 19 Bilateral sPE* -** 61 RUL 1 3.4 mm 14 mm Patient 7 10 19 - MSSA^^ 23 RML 1 5.14 mm 24 mm Patient 8 5 20 - -** 116 RUL 2 5.8 mm 39 mm Patient 9 6 20 Bilateral sPE* K. pneumoniae** 70 LLL 1 1.58 mm 47 mm Patient 10 6 12 - K. pneumoniae** 50 LUL 1 5.4 mm 52 mm Patient 11 6 13 Bilateral sPE* -^^ 34 RLL+LLL 3 3.7 mm 49 mm Patient 12 8 9 - MRSA^^ 26 LLL 1 3.2 mm 44 mm Patient 13 5 9 - - 82 RUL 1 7 mm 11 mm Patient 14 5 7 - - 32 RLL 1 6 mm 9 mm Patient 15 5 12 - Galactomannan+** 74 RUL+LUL 2 5.1 mm 37 mm Discussion Peripheral, bilateral, diffuse ground-glass opacities or multifocal ground-glass opacities of rounded morphology with or without consolidation, as well as halo and inverted halo signs, are common CT findings of COVID-19 in the acute period [9]. During the healing stages of the disease, the lung lesions can gradually disappear and rarely fibrosis can be seen. However, long-term imaging patterns are still not known requiring further observations [10]. Cavitary lung lesions are classically known to be related to fungal, mycobacterial, autoimmune, parasitic, or neoplastic etiologies. Increased use of steroids and anti-TNF drugs in the treatment of SARS-CoV-2 patients can also be the cause of cavitation due to secondary infections such as Mycobacterium tuberculosis complex detected in two of our cases. Patients who developed cavitation during follow-up should also be checked carefully for fungal infections and secondary bacterial infections. Five of our patients had bacterial growth which could lead to cavitary lesions (Klebsiella pneumoniae, MSSA, MRSA) and two were galactomannan positive in bronchoalveolar lavage fluid. Pulmonary embolism is a known cause of infarction and lung cavitation, and SARS-CoV-2 patients have a higher tendency toward coagulation [11]. Six (40%) of our patients had documented pulmonary embolism. However, in some patients, no underlying condition is found to cause cavitary lesions on chest CT, and the only reason may be the COVID-19 virus itself. Although the specific process of cavitation in COVID-19 patients is unknown, autopsy reports have suggested that it may arise following diffuse alveolar injury, intra-alveolar hemorrhage, and parenchymal cell necrosis [12]. Patients with more severe disease can have a higher tendency to develop cavitary lesions. All patients in our study population were hypoxemic and hospitalized. Their worst WHO clinical progression scores ranged between 5 and 10 during hospitalization. Thirteen patients have increased neutrophil/lymphocyte ratio and the same patients had lymphopenia on admission. Liu et al. found a relationship between poor prognosis in COVID-19 patients and increased neutrophil/lymphocyte ratio [13]. Another study showed lymphopenia at the first presentation of COVID-19 to be associated with disease severity [14]. Compared to women, men with COVID-19 experience more severe disease and higher mortality. The male sex is an independent risk factor for developing more severe COVID-19 disease [15]. Fourteen (93.3) patients were male in our study population, whereas the only female patient was severely obese (BMI >40 kg/m2). Dose-response relationship between higher BMI and severe COVID-19-associated illness has been highlighted in previous reports, with obesity being another risk factor for severe infection [16]. These demographic characteristics and laboratory values support cavitary lesions developing in patients with more severe COVID-19 in our study. Our study had some limitations. This is a single-centered, descriptive, retrospective analysis of COVID-19 patients. Every patient with cavitation did not have a chance to undergo an investigation for pulmonary embolism accurately or bronchoalveolar lavage because of their clinical instability and high oxygen demand. Because only patients who underwent chest CT were screened retrospectively, patients who developed similar cavitary lesions during the study period would have been missed. Conclusions Lung cavitation remains a rare occurrence in the disease course of COVID-19 patients. Every patient who developed a cavitary lesion during the post-COVID-19 follow-up must be evaluated individually according to their symptoms and findings. Bronchoscopic evaluation and scanning for pulmonary embolism should be done in appropriate patients to determine secondary reasons for cavitation. This descriptive study showed that cavitary lesions can develop in patients with severe disease, but more comprehensive studies with a control group are needed to reach a definitive conclusion. The need for prophylaxis (e.g., antifungal, antituberculosis) before administering long-term steroids or anti-TNF drugs could also be a future topic of discussion in COVID-19 patients. Human Ethics Animal Ethics Consent was obtained or waived by all participants in this study. Marmara University Ethics Committee issued approval 5.11.2021;1224 Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. The authors have declared that no competing interests exist. ==== Refs References 1 WHO declares COVID-19 a pandemic Acta Biomed Cucinotta D Vanelli M 157 160 91 2020 32191675 2 Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention JAMA Wu Z McGoogan JM 1239 1242 323 2020 32091533 3 Frequency and distribution of chest radiographic findings in patients positive for COVID-19 Radiology Wong HY Lam HY Fong AH 0 8 296 2020 4 Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA - secondary publication J Thorac Imaging Simpson S Kay FU Abbara S 219 227 35 2020 32324653 5 Large pulmonary cavity in COVID-19 cured patient case report Ann Palliat Med Chen Y Chen W Zhou J Sun C Lei Y 5786 5791 10 2021 32527136 6 Republic of Turkey 5 2021 2021 https://covid19.saglik.gov.tr/TR-66301/covid-19-rehberi.html 7 A minimal common outcome measure set for COVID-19 clinical research Lancet Infect Dis 0 7 20 2020 8 CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) Eur Radiol Li K Fang Y Li W 4407 4416 30 2020 32215691 9 COVID-19 pneumonia: a pictorial review of CT findings and differential diagnosis Egypt J Radiol Nucl Med Shirani F Shayganfar A Hajiahmadi S 38 52 2021 10 CT imaging features of 2019 novel coronavirus (2019-nCoV) Radiology Chung M Bernheim A Mei X 202 207 295 2020 32017661 11 High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Intensive Care Med Helms J Tacquard C Severac F 1089 1098 46 2020 32367170 12 Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction Histopathology Menter T Haslbauer JD Nienhold R 198 209 77 2020 32364264 13 Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 J Infect Liu Y Du X Chen J 0 81 2020 14 Lymphopenia as a biological predictor of outcomes in COVID-19 patients: a nationwide cohort study Cancers (Basel) Lee J Park SS Kim TY Lee DG Kim DW 471 13 2021 33530509 15 Men and COVID-19: a pathophysiologic review Am J Mens Health Lipsky MS Hung M 1557988320954021 14 2020 32936693 16 Body mass index and risk for COVID-19-related hospitalization, intensive care unit admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020 MMWR Morb Mortal Wkly Rep Kompaniyets L Goodman AB Belay B 355 361 70 2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7010e4.htm 33705371